Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
2(66.7%)
N/A
1(33.3%)
3Total
Phase 4(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05019365Unknown

Investigating the Long-term Cardiac Sequelae of Trastuzumab Therapy

Role: collaborator

NCT03593941Completed

Ageing Gut Brain Interactions

Role: collaborator

NCT01656005Phase 4Completed

Beta Blocker Therapy in Moderate to Severe COPD

Role: collaborator

NCT02039011Phase 4Completed

Ultra-long Acting Bronchodilator Therapy in Asthmatics

Role: collaborator

NCT00355602Not ApplicableCompleted

Antibiotics for the Treatment of Ulcerative Colitis

Role: collaborator

All 5 trials loaded